Similarly, a biopsy sparing approach in IgA deficient patients with positive IgG-based serological tests is not recommended in cases of value >10 ULN (21), and the recommendation for the follow-up of patients with IgA deficiency are scarce. The gene discussed is CD79A; the disease is selective IgA deficiency disease.